Amgen Inc. Unrecognized Tax Benefits, Income Tax Penalties and Interest Expense
Amgen Inc. (AMGN) reported Unrecognized Tax Benefits, Income Tax Penalties and Interest Expense of $264.00 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-13.
Financial Statements › Expense Statement › Interest Expense
us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense · last filed 2026-02-13
- Amgen Inc. unrecognized tax benefits, income tax penalties and interest expense for fiscal 2025 was $264.00M, a 6.38% decline from fiscal 2024.
- Amgen Inc. unrecognized tax benefits, income tax penalties and interest expense for fiscal 2024 was $282.00M, a 1.74% decline from fiscal 2023.
- Amgen Inc. unrecognized tax benefits, income tax penalties and interest expense for fiscal 2023 was $287.00M, a 51.85% increase from fiscal 2022.
- Amgen Inc. unrecognized tax benefits, income tax penalties and interest expense for fiscal 2022 was $189.00M, a 92.86% increase from fiscal 2021.
| Period end | Unrecognized Tax Benefits, Income Tax Penalties and Interest Expense 12 month |
|---|---|
| 2025-12-31 | $264.00M 10-K · filed 2026-02-13 |
| 2024-12-31 | $282.00M 10-K · filed 2026-02-13 |
| 2023-12-31 | $287.00M 10-K · filed 2026-02-13 |
| 2022-12-31 | $189.00M 10-K · filed 2025-02-14 |
| 2021-12-31 | $98.00M 10-K · filed 2024-02-14 |
| 2020-12-31 | $116.00M 10-K · filed 2023-02-09 |
| 2019-12-31 | $198.00M 10-K · filed 2022-02-16 |
| 2018-12-31 | $137.00M 10-K · filed 2021-02-09 |
| 2017-12-31 | $56.00M 10-K · filed 2020-02-12 |
| 2016-12-31 | $125.00M 10-K · filed 2019-02-13 |
| 2015-12-31 | $17.00M 10-K · filed 2018-02-13 |
| 2014-12-31 | $35.00M 10-K · filed 2017-02-14 |
| 2013-12-31 | $32.00M 8-K · filed 2016-10-31 |
| 2012-12-31 | $30.00M 10-K · filed 2015-02-19 |
| 2011-12-31 | $23.00M 10-K · filed 2014-02-24 |
| 2010-12-31 | $41.00M 10-K · filed 2013-02-27 |
| 2009-12-31 | $57.00M 10-K · filed 2012-02-29 |
| 2008-12-31 | $71.00M 10-K · filed 2011-02-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| GILEAD SCIENCES, INC. (GILD) | United States | $185.522B | -48.37 |
| Moderna, Inc. (MRNA) | United States | $77.819B | -8.86 |
| Revolution Medicines, Inc. (RVMD) | United States | $42.805B | -22.69 |
| BIOGEN INC. (BIIB) | United States | $33.427B | 19.60 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |